ASRT - Assertio Therapeutics Inc Stock Price, Fair Value and News

$0.89+0.05 (+5.95%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ASRT Price Action

Last 7 days

-3.3%

Last 30 days

-6.3%

Last 90 days

-31.5%

Trailing 12 Months

-18.3%

ASRT RSI Chart

ASRT Valuation

Market Cap

85.0M

Price/Earnings (Trailing)

-1.24

Price/Sales (Trailing)

0.68

EV/EBITDA

-4.6

Price/Free Cashflow

4.07

ASRT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ASRT Fundamentals

ASRT Revenue

Revenue (TTM)

125.8M

Rev. Growth (Yr)

-18.03%

Rev. Growth (Qtr)

-6.17%

ASRT Earnings

Earnings (TTM)

-68.5M

Earnings Growth (Yr)

98.96%

Earnings Growth (Qtr)

20.5%

ASRT Profitability

EBT Margin

-33.94%

Return on Equity

-52.47%

Return on Assets

-24.81%

Free Cashflow Yield

24.57%

ASRT Investor Care

Shares Dilution (1Y)

0.85%

Diluted EPS (TTM)

-0.93

ASRT Alerts

1 major insider buys recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	142.1M	132.2M	125.8M	0
2023	162.2M	168.0M	169.4M	152.1M
2022	120.7M	130.5M	139.2M	156.2M
2021	112.2M	117.0M	107.9M	111.0M
2020	198.7M	167.9M	137.1M	106.3M
2019	0	0	0	229.5M

Get all data in R, Python etc through our Historical Stock Data APIs

About Assertio Therapeutics Inc

Assertio Holdings, Inc., a commercial pharmaceutical company, provides medicines in the areas of neurology, rheumatology, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.

CEO	Mr. Daniel A. Peisert
WEBSITE	assertiotx.com
SECTOR	Healthcare
INDUSTRY	Drug Manufacturers Specialty & Generic
EMPLOYEES	30

Assertio Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Assertio Therapeutics Inc? What does ASRT stand for in stocks?

ASRT is the stock ticker symbol of Assertio Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Assertio Therapeutics Inc (ASRT)?

As of Fri Dec 20 2024, market cap of Assertio Therapeutics Inc is 84.98 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ASRT stock?

You can check ASRT's fair value in chart for subscribers.

Is Assertio Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ASRT is over valued or under valued. Whether Assertio Therapeutics Inc is cheap or expensive depends on the assumptions which impact Assertio Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ASRT.

What is Assertio Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, ASRT's PE ratio (Price to Earnings) is -1.24 and Price to Sales (PS) ratio is 0.68. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ASRT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Assertio Therapeutics Inc's stock?

In the past 10 years, Assertio Therapeutics Inc has provided -0.344 (multiply by 100 for percentage) rate of return.